A preparation method of tofacitinib impurity I
By using the reaction of monoethyl malonic acid potassium salt and DMTMM condensant in the preparation of impurities of the torrentibu, combined with potassium hydroxide treatment, the problems of cumbersome operation and low purity in the existing methods are solved, and high efficiency is achieved. The preparation of TFTB-I, a high-purity tofatite-related impurity, is suitable for mass production.
Patent Information
- Application Number
- CN202010328888.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-04-23
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-04-23
AI Technical Summary
The existing method of preparing impurities of sturbine methods is complicated to operate, has low purity and low yield, making it difficult to meet the needs of mass production.
Compound 1 is used to react with potassium salt of monoethyl malonic acid and a condensant in an organic solvent, and then the pH is adjusted in an aqueous potassium hydroxide solution. High-purity tofatibu-related impurity TFTB is obtained by extraction and rotary evaporation- I, using monosubstituted potassium salt and DMTMM condensant, simplifying operation and improving reaction efficiency.
The preparation of TFTB-I, a tofatite-related impurity, is simple to operate, is suitable for mass production, and reduces the generation of side reactions.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to a method for preparing tofacitinib-related impurities. Background Art
[0002] Tofacitinib citrate, chemical name is (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-carbonyl-1-piperidinepropionitrile-2-hydroxy-1,2,3-propane tricarboxylate. Tofacitinib citrate is a new oral JAK inhibitor developed by Pfizer, USA. It was approved by the US FDA in November 2012 under the trade name Xeljanz. It is used to treat adult patients with moderate to severe active rheumatoid arthritis who have an inadequate response or intolerance to methotrexate treatment. The structural formula is as follows:
[0003]
[0004] In the process of new drug research and development, the quality of the drug is an important criterion for measuring the quality of the drug. The quality of the drug is first determined by the efficacy and toxic side effects of the drug itself, that is, the effectiveness and safety of the drug. The content of the active ingredient of the drug is an important indicator of the purity of the drug, and the impurities present in the drug directly affect the efficacy of the drug and may cause toxic side effects. The impurities of the drug are other chemical substances other than the drug introduced or produced during the production, storage and transportation process. The presence of impurities not only affects the purity of the drug, but also brings non-therapeutic toxic side effects, which must be controlled. In order to use drugs safely and effectively, the quality standards of drugs have relatively strict regulations on the purity of the active ingredients of the drugs and the limits of impurities. Generally speaking, drug impurities exceeding 0.1% should be identified and quantified by selective methods.
[0005] For drug developers, the main task is not only to obtain high-quality APIs and develop efficient synthesis processes, but also to study the types and sources of impurities in APIs and how to control the generation of process impurities. Usually, researchers will first target the impurities generated in the synthesis process, and then develop efficient impurity synthesis routes to obtain a large number of impurity reference substances to ensure the quality testing of each batch of APIs, such as impurity HPLC positioning and impurity content determination.
[0006] At present, there are many reports on tofacitinib-related impurities in the literature, but there are few studies on the preparation methods of impurities. For example, tofacitinib is very easy to form hydrolysis impurities when it encounters acid during the acylation process. In addition, the stability study data of the raw material drug shows that tofacitinib citrate can still slowly degrade during storage to produce the impurity 3-((3R, 4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropionic acid, the structure of which is shown below:
[0007]
[0008] Although patent CN109336892A has reported a method for preparing the impurity, the process uses tofacitinib as the reaction material, controls the temperature under acidic conditions to completely hydrolyze tofacitinib, and then neutralizes, extracts, and crystallizes the reaction solution to obtain the tofacitinib hydrolysis impurity; however, the method is cumbersome to operate, and the two hydrolysis impurities obtained are difficult to separate, so the purity is not high and the yield is only 31.7%.
[0009] As an important part of drug development and drug registration application, impurity research determines the preparation method of tofacitinib-related impurity compounds and provides qualified reference materials for impurity research, which can play a positive role in quality control. Therefore, it is of great significance to study and provide a new and efficient preparation method for tofacitinib-related impurities. Summary of the invention
[0010] In view of the problems of low yield and large amount of impurities generated in the current process of preparing tofacitinib impurities, the present invention aims to provide a technical method suitable for mass production of tofacitinib impurity I (TFTB-I) with simple operation, mild reaction conditions, high product yield and high purity.
[0011] The specific technical contents of the present invention are as follows:
[0012]
[0013] Step 1: dissolving compound 1 in an organic solvent, adding compound 2, potassium salt of monoethyl malonate, a base and a condensing agent, stirring for reaction, adding purified water after the reaction is completed, extracting, retaining the organic phase, and rotary evaporating to obtain a solid product, compound 3;
[0014] Step 2: Add compound 3 to the mixed solvent and stir evenly, add potassium hydroxide aqueous solution dropwise to the reaction bottle, stir to react, add organic solvent to the reaction system for extraction after the reaction is completed, retain the aqueous phase, adjust the pH to 3-4, and rotary evaporate to obtain a solid, re-add the solvent to dissolve, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib-related impurity TFTB-I.
[0015] Preferably, the organic solvent in step 1 is ethyl acetate, dichloromethane, n-hexane, petroleum ether or a combination thereof; preferably dichloromethane.
[0016] Preferably, the mass volume ratio of compound 1 to the organic solvent in step 1 is 1:5-20, g / ml; preferably 1:10, g / ml.
[0017] Preferably, the molar ratio of compound 1 in step 1 to potassium salt of monoethyl malonate is 1:0.9-1.5; preferably 1:1.
[0018] Preferably, the reaction temperature in step 1 is 10-40°C, preferably 20°C.
[0019] Preferably, the reaction time in step 1 is 3 to 8 hours, preferably 5 to 6 hours.
[0020] Preferably, the condensation agent in step 1 is 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM).
[0021] Further preferably, in step 1, the molar ratio of compound 1, base and condensing agent is 1:0.9-1.2:1-1.5, preferably 1:1:1.3.
[0022] Preferably, the base used in step 1 is triethylamine or N,N-diisopropylethylamine (DIPEA), preferably triethylamine.
[0023] Preferably, the mixed solvent described in step 2 is a combination of an organic solvent and water; wherein the organic solvent is selected from methanol, ethanol, tetrahydrofuran, acetone, acetonitrile or a combination thereof; preferably tetrahydrofuran.
[0024] Further preferably, the volume ratio of the organic solvent to water in the mixed solvent described in step 2 is 10 to 15:1.
[0025] Preferably, the mass volume ratio of the compound 3 described in step 2 to the mixed solvent is 1:5-20, g / ml; preferably 1:10, g / ml.
[0026] Preferably, the aqueous potassium hydroxide solution in step 2 is a 10% solution by mass, wherein the mass volume ratio of compound 3 to the 10% aqueous potassium hydroxide solution is 1:8-12, g / ml; preferably 1:9, g / ml.
[0027] Preferably, the reaction temperature in step 2 is 10-30°C, preferably 15°C.
[0028] Preferably, the reaction time in step 2 is 1 to 3 h, preferably 1.5 h.
[0029] Preferably, the organic solvent used for extraction in step 2 is ethyl acetate, n-hexane or petroleum ether.
[0030] Preferably, the acid used to adjust the pH in step 2 is dilute hydrochloric acid or dilute sulfuric acid.
[0031] Preferably, the solvent added again in step 2 is acetonitrile, methanol, ethanol or acetone.
[0032] Compared with the prior art, the technical effects achieved by the present invention are:
[0033] When using a monosubstituted potassium salt for the reaction, the intermediate can be directly hydrolyzed without purification to obtain a product with high purity and yield, and the potassium salt is stable, cheap and easy to obtain. The reaction operation using DMTMM as a condensation agent is simple, the reaction conditions are mild, and compared with commonly used condensation reagents, the reaction system has fewer side reactions, almost no corresponding impurity by-products are produced, and the reaction is efficient and has a high yield, which is suitable for mass production. DETAILED DESCRIPTION
[0034] The present invention is further illustrated by the following examples. It should be correctly understood that the examples of the present invention are only used to illustrate the present invention, rather than to limit the present invention. Therefore, simple improvements to the present invention based on the method of the present invention are all within the scope of protection claimed by the present invention.
[0035] Example 1
[0036] Add 30.0 g of compound 1 and 300 mL of dichloromethane to the reaction bottle, stir evenly, add 20.4 g of potassium monoethyl malonate, 17 ml of triethylamine, and 44.10 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 20°C for 5 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0037] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 400 ml of 10% potassium hydroxide aqueous solution dropwise to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporate to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 95.3%, HPLC: 99.6%, MS (m / z): 331.16 [M+H] + .
[0038] Example 2
[0039] Add 30.0 g of compound 1 and 300 mL of dichloromethane to the reaction bottle, stir evenly, add 20.4 g of potassium monoethyl malonate, 15 ml of triethylamine, and 33.92 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 20°C for 5 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0040] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 440 ml of 10% potassium hydroxide aqueous solution to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporating to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 90.1%, HPLC: 99.2%. MS (m / z): 331.16 [M+H] + .
[0041] Example 3
[0042] Add 30.0 g of compound 1 and 300 mL of dichloromethane to the reaction bottle, stir evenly, add 20.4 g of potassium monoethyl malonate, 20 ml of triethylamine, and 50.9 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 25°C for 5 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0043] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 400 ml of 10% potassium hydroxide aqueous solution to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporating to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 91.2%, HPLC: 99.3%, MS (m / z): 331.16 [M+H] + .
[0044] Example 4
[0045] Add 30.0g of compound 1 and 150mL of dichloromethane to the reaction bottle, stir evenly, add 18.4g of potassium monoethyl malonate, 17ml of triethylamine, and 44.10g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 15°C for 8h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain the solid product compound 3, which is directly subjected to the next step of reaction without treatment.
[0046] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 350 ml of 10% potassium hydroxide aqueous solution dropwise to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporating to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 88.5%, HPLC: 99.1%, MS (m / z): 331.16 [M+H] + .
[0047] Example 5
[0048] Add 30.0 g of compound 1 and 300 mL of dichloromethane to the reaction bottle, stir evenly, add 20.4 g of potassium monoethyl malonate, 17 ml of triethylamine, and 44.10 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 20°C for 5 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0049] Add 200 ml of tetrahydrofuran and 20 ml of water to compound 3, stir evenly, add 400 ml of 10% potassium hydroxide aqueous solution dropwise to the reaction bottle, and stir at 10°C for 3 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporate to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 89.7%, HPLC: 99.0%, MS (m / z): 331.16 [M+H] + .
[0050] Example 6
[0051] Add 30.0 g of compound 1 and 600 mL of dichloromethane to the reaction bottle, stir evenly, add 30.6 g of potassium monoethyl malonate, 17 ml of triethylamine, and 44.10 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 40°C for 3 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0052] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 400 ml of 10% potassium hydroxide aqueous solution to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of n-hexane to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporating to obtain a solid. Add 500 ml of ethanol to the solid, stir, filter out the solid, and evaporate the filtrate to dryness. The target product, tofacitinib impurity TFTB-I, has a yield of 90.2%, HPLC: 98.1%, MS (m / z): 331.16 [M+H] + .
[0053] Example 7
[0054] Add 30.0 g of compound 1 and 300 mL of ethyl acetate to the reaction bottle, stir evenly, add 20.4 g of potassium monoethyl malonate, 17 ml of triethylamine, and 44.10 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 20°C for 5 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0055] 800 ml of tetrahydrofuran and 53 ml of water were added to compound 3, and the mixture was stirred evenly. 400 ml of 10% potassium hydroxide aqueous solution was added dropwise to the reaction flask, and the mixture was stirred at 30°C for 1 hour. 400 ml of petroleum ether was added to the reaction system, and the mixture was extracted. The aqueous phase was retained, and the pH was adjusted to 3 with aqueous hydrochloric acid solution. The solid was obtained by rotary evaporation. 500 ml of acetonitrile was added to the solid, and the mixture was stirred. The solid was filtered out, and the filtrate was evaporated to dryness to obtain the target product, tofacitinib impurity TFTB-I, with a yield of 90.0%, HPLC: 98.1%, MS (m / z): 331.16 [M+H] + .
[0056] Example 8
[0057] Add 30.0 g of compound 1 and 300 mL of dichloromethane to the reaction bottle, stir evenly, add 20.4 g of potassium monoethyl malonate, 25 ml of triethylamine, and 67.8 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 20°C for 6 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0058] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 400 ml of 10% potassium hydroxide aqueous solution dropwise to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporate to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 81.5%, HPLC: 96.4%, MS (m / z): 331.16 [M+H] + .
[0059] Example 9
[0060] Add 30.0 g of compound 1 and 300 mL of dichloromethane to the reaction bottle, stir evenly, add 40.8 g of potassium monoethyl malonate, 17 ml of triethylamine, and 44.10 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence, react at 50°C for 2 h, add purified water after the reaction, extract, retain the organic phase, and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0061] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 400 ml of 10% potassium hydroxide aqueous solution to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporating to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 83.2%, HPLC: 97.3%, MS (m / z): 331.16 [M+H] + .
[0062] Example 10
[0063] Add 30.0 g of compound 1 and 300 mL of n-hexane into a reaction bottle and stir evenly. Then add 20.4 g of potassium monoethyl malonate, 17 ml of triethylamine, and 44.10 g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride in sequence. React at 20°C for 5 h. After the reaction, add purified water and extract. Retain the organic phase and rotary evaporate to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0064] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 500 ml of 10% potassium hydroxide aqueous solution to the reaction bottle, and stir at 30°C for 4 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporating to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 83.6%, HPLC: 97.1%, MS (m / z): 331.16 [M+H] + .
[0065] Comparative Example 1
[0066] Add 30.0 g of compound 1 and 300 mL of dichloromethane to the reaction bottle, stir evenly, add 20.4 g of potassium monoethyl malonate, 17 ml of triethylamine, 16.5 g of HOBT and 23.5 g of EDCI in sequence, and react at 20°C for 6 h. After the reaction, add a small amount of purified water for extraction, retain the organic phase, and evaporate the organic phase to obtain a solid product, compound 3, which is directly subjected to the next step of reaction without treatment.
[0067] Add 400 ml of tetrahydrofuran and 40 ml of water to compound 3, stir evenly, add 400 ml of 10% potassium hydroxide aqueous solution to the reaction bottle, and stir at 15°C for 1.5 hours. Add 400 ml of ethyl acetate to the reaction system, extract, retain the aqueous phase, adjust the pH to 3 with hydrochloric acid aqueous solution, and evaporating to obtain a solid. Add 500 ml of acetonitrile to the solid, stir, filter out the solid, and evaporate the filtrate to dryness to obtain the target product tofacitinib impurity TFTB-I, with a yield of 70.2%, HPLC: 95.3%, MS (m / z): 331.16 [M+H] + .
Claims
1. A method for preparing tofacitinib impurity I, It is characterized in that The specific preparation steps include: 30.0g of compound 1, 300mL of dichloromethane, 20.4g of potassium monoethyl malonate, 17ml of triethylamine, and 44.10g of 4-(4,6-dimethoxytriazine)-4-methylmorpholine hydrochloride are added in sequence, reacting at 20°C for 5h, adding purified water after the reaction, extracting, retaining the organic phase, and rotary evaporating to obtain a solid product compound 3, which is directly subjected to the next step of reaction without treatment; 400ml of tetrahydrofuran and 40ml of water are added to compound 3, 400ml of a 10% potassium hydroxide aqueous solution is added dropwise to a reaction bottle, and stirred at 15°C for 1.5 hours; 400ml of ethyl acetate is added to the reaction system, extracted, the aqueous phase is retained, the pH is adjusted to 3 with a hydrochloric acid aqueous solution, and a solid is obtained by rotary evaporation, 500ml of acetonitrile is added to the solid, stirred, the solid is filtered out, and the filtrate is evaporated to dryness to obtain the target product tofacitinib impurity TFTB-I; 。
